Novo Nordisk Faces $70B Blow as New CEO Steps In Amidst Weight-Loss Drug Turmoil

Novo Nordisk's market value fell by $70 billion following a profit warning and the appointment of Maziar Mike Doustdar as the new CEO. The company faces increased competition in the obesity drug market and challenges from compounded versions of its weight-loss drugs, impacting its U.S. sales and outlook.

Novo Nordisk, the Danish pharmaceutical giant, saw its market value plummet by $70 billion after issuing a profit warning and announcing the appointment of Maziar Mike Doustdar as its new CEO. The company is grappling with mounting competition in the obesity drug market, with compounded versions of its drug Wegovy cutting into profits.

The appointment of Doustdar, an insider with extensive international experience, comes at a critical time for Novo Nordisk. The company revised its 2025 sales growth forecast significantly downward, sparking concerns among investors about its competitive edge in the U.S. market. Its stock plunged nearly 30% before stabilizing somewhat.

The new CEO faces the daunting task of reinvigorating U.S. operations, where Novo has lost its lead to American rival Eli Lilly. Doustdar must navigate the challenges posed by illegal compounding and revive investor trust in the company's ability to innovate and regain market share.

(With inputs from agencies.)